<DOC>
	<DOCNO>NCT00937664</DOCNO>
	<brief_summary>The primary purpose study find maximum tolerate dose experimental drug call AZD7762 give approve drug gemcitabine base side effect experience patient receive drug .</brief_summary>
	<brief_title>Safety Tolerability Study AZD7762 Combination With Gemcitabine</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>Japanese patient advance solid tumor standard treatment exist longer effective . Must suitable treatment gemcitabine Relatively good overall health cancer Poor bone marrow function ( produce enough blood cell ) . Poor liver kidney function . Serious heart condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Phase I</keyword>
	<keyword>cancer</keyword>
	<keyword>solid tumor</keyword>
	<keyword>advanced solid malignancy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>combination treatment</keyword>
	<keyword>CHK inhibitor</keyword>
	<keyword>Japanese</keyword>
</DOC>